Objectives: Dual antiplatelet therapy (DAPT), consisting of clopidogrel and aspirin, is the main-stay treatment of acute coronary syndromes (ACS). However, major adverse cardiovascular events may occur even in patients undergoing DAPT, and this has been related to the variable pharmacodynamic efficacy of these drugs, especially clopidogrel. Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are novel inflammatory markers for cardiovascular risk stratification, which may reflect an inflammatory state and thus high on-treatment platelet reactivity (HPR)
Background/Aims Prolonged dual antiplatelet therapy (DAPT) with aspirin and clopidogrel beyond 1 yea...
The value of platelet function testing (PFT) in predicting clinical outcomes and guiding P2Y12-inhib...
Summary High platelet reactivity (HPR) during dual antiplatelet therapy is a marker of vascular risk...
Objectives: Dual antiplatelet therapy (DAPT), consisting of clopidogrel and aspirin, is the main-sta...
Background: Neutrophil to lymphocyte ratio (NLR) has emerged as a useful and easy-to-assess prognost...
LetterOver the past ten years, a large body of evidence clearly demonstrated that acute coronary syn...
Item does not contain fulltextOBJECTIVE: High on-treatment platelet reactivity (HRPR) is associated ...
Introduction: Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are two me...
Low response to antiplatelet agents has been associated to an increased risk of thrombotic complicat...
High platelet reactivity (HPR) during dual antiplatelet therapy is a marker of vascular risk, in par...
Background: Platelet reactivity is closely associated with adverse events in percutaneous coronary i...
SummaryHigh platelet reactivity (HPR) during dual antiplatelet therapy is a marker of vascular risk,...
High on-treatment platelet reactivity (HPR) has been identified as an independent risk factor for is...
Background. In acute coronary syndrome (ACS), inflammation and redox response are associated with in...
Background: The aim of this study was to investigate the relationship between neutrophil to lymphocy...
Background/Aims Prolonged dual antiplatelet therapy (DAPT) with aspirin and clopidogrel beyond 1 yea...
The value of platelet function testing (PFT) in predicting clinical outcomes and guiding P2Y12-inhib...
Summary High platelet reactivity (HPR) during dual antiplatelet therapy is a marker of vascular risk...
Objectives: Dual antiplatelet therapy (DAPT), consisting of clopidogrel and aspirin, is the main-sta...
Background: Neutrophil to lymphocyte ratio (NLR) has emerged as a useful and easy-to-assess prognost...
LetterOver the past ten years, a large body of evidence clearly demonstrated that acute coronary syn...
Item does not contain fulltextOBJECTIVE: High on-treatment platelet reactivity (HRPR) is associated ...
Introduction: Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are two me...
Low response to antiplatelet agents has been associated to an increased risk of thrombotic complicat...
High platelet reactivity (HPR) during dual antiplatelet therapy is a marker of vascular risk, in par...
Background: Platelet reactivity is closely associated with adverse events in percutaneous coronary i...
SummaryHigh platelet reactivity (HPR) during dual antiplatelet therapy is a marker of vascular risk,...
High on-treatment platelet reactivity (HPR) has been identified as an independent risk factor for is...
Background. In acute coronary syndrome (ACS), inflammation and redox response are associated with in...
Background: The aim of this study was to investigate the relationship between neutrophil to lymphocy...
Background/Aims Prolonged dual antiplatelet therapy (DAPT) with aspirin and clopidogrel beyond 1 yea...
The value of platelet function testing (PFT) in predicting clinical outcomes and guiding P2Y12-inhib...
Summary High platelet reactivity (HPR) during dual antiplatelet therapy is a marker of vascular risk...